News & Views
Supply Agreement Opens Access to Oncology Medicines
Jan 10 2020
Following a recent agreement signing, global pharmaceutical company and service partner Inceptua Group now offer Bendalis GmbH’s range of generic oncology drugs and specialist therapeutic agents, enabling clinical trial sponsors quick access to Brexit-safe oncology standard of care medicines produced within the European Union.
“With this agreement Bendalis and Inceptua join forces to ensure optimal sourcing and supply of medicines for use in oncology clinical trials to our clients. Together, we share a mission to provide uninterrupted access for patients to high quality products through a secure and robust supply chain,” said Alan Raffensperger, CEO, Inceptua Group.
As a part of the agreement, Bendalis will maintain stock of specific products on a consignment basis, providing contingency against manufacturing issues, stock-out situations and mitigation of study delays which would impact both patients and sponsors.
“In the oncology space we experience a growing need and demand for products. We see Inceptua as the ideal partner to handle the distribution and help optimise the clinical trial supply for clients. A consistent and secure supply of products is a critical component in clinical trials and together we can offer a flexible yet reliable solution, helping clients minimise overage and reduce costs,” says Christian Parvany, CEO, Bendaliss.
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE